Your request to link to rcsb for Androgen receptor

• 1E3G: human androgen receptor ligand binding in complex with the ligand metribolone (r1881) (10.1074/JBC.M004571200 )
• 1GS4: structural basis for the glucocorticoid response in a mutant human androgen receptor (arccr) derived from an androgen-independent prostate cancer (10.1021/JM011072J )
• 1I37: crystal structure of the rat androgen receptor ligand binding domain complex with dihydrotestosterone (10.1073/PNAS.081565498 )
• 1I38: crystal structure of the rat androgen receptor ligand binding domain t877a mutant complex with dihydrotestosterone (10.1073/PNAS.081565498 )
• 1R4I: crystal structure of androgen receptor dna-binding domain bound to a direct repeat response element (10.1073/PNAS.0401123101 )
• 1T5Z: crystal structure of the androgen receptor ligand binding domain (lbd) with dht and a peptide derived from its physiological coactivator ara70 (10.1074/JBC.M407046200 )
• 1T63: crystal structure of the androgen receptor ligand binding domain with dht and a peptide derived from its physiological coactivator grip1 nr box3 (10.1074/JBC.M407046200 )
• 1T65: crystal structure of the androgen receptor ligand binding domain with dht and a peptide derived form its physiological coactivator grip1 nr box 2 bound in a non-helical conformation (10.1074/JBC.M407046200 )
• 1T73: crystal structure of the androgen receptor ligand binding domain in complex with a fxxff motif (10.1371/JOURNAL.PBIO.0020274 )
• 1T74: crystal structure of the androgen receptor ligand binding domain in complex with a wxxlf motif (10.1371/JOURNAL.PBIO.0020274 )
• 1T76: crystal structure of the androgen receptor ligand binding domain in complex with a wxxvw motif (10.1371/JOURNAL.PBIO.0020274 )
• 1T79: crystal structure of the androgen receptor ligand binding domain in complex with a fxxlw motif (10.1371/JOURNAL.PBIO.0020274 )
• 1T7F: crystal structure of the androgen receptor ligand binding domain in complex with a lxxll motif (10.1371/JOURNAL.PBIO.0020274 )
• 1T7M: crystal structure of the androgen receptor ligand binding domain in complex with a fxxyf motif (10.1371/JOURNAL.PBIO.0020274 )
• 1T7R: crystal structure of the androgen receptor ligand binding domain in complex with a fxxlf motif (10.1371/JOURNAL.PBIO.0020274 )
• 1T7T: crystal structure of the androgen receptor ligand binding domain in complex with 5-alpha dihydrotestosterone (10.1371/JOURNAL.PBIO.0020274 )
• 1XJ7: complex androgen receptor lbd and rac3 peptide (10.1074/JBC.M407046200 )
• 1XNN: crystal structure of the rat androgen receptor ligand binding domain t877a mutant complex with (3a-alpha-,4- alpha 7-alpha-,7a-alpha-)-3a,4,7,7a-tetrahydro-2-(4-nitro- 1-naphthalenyl)-4,7-ethano-1h-isoindole-1,3(2h)-dione. (10.1016/J.BMCL.2004.10.085 )
• 1XOW: crystal structure of the human androgen receptor ligand binding domain bound with an androgen receptor nh2-terminal peptide, ar20-30, and r1881 (10.1016/J.MOLCEL.2004.09.036 )
• 1XQ3: crystal structure of the human androgen receptor ligand binding domain bound with r1881 (10.1016/J.MOLCEL.2004.09.036 )
• 1Z95: crystal structure of the androgen receptor ligand-binding domain w741l mutant complex with r-bicalutamide (10.1073/PNAS.0500381102 )
• 2AM9: crystal structure of human androgen receptor ligand binding domain in complex with testosterone (10.1110/PS.051905906 )
• 2AMA: crystal structure of human androgen receptor ligand binding domain in complex with dihydrotestosterone (10.1110/PS.051905906 )
• 2AMB: crystal structure of human androgen receptor ligand binding domain in complex with tetrahydrogestrinone (10.1110/PS.051905906 )
• 2AO6: crystal structure of the human androgen receptor ligand binding domain bound with tif2(iii) 740-753 peptide and r1881 (10.1016/J.MOLCEL.2004.09.036 )
• 2AX6: crystal structure of the androgen receptor ligand binding domain t877a mutant in complex with hydroxyflutamide (10.1074/JBC.M507464200 )
• 2AX7: crystal structure of the androgen receptor ligand binding domain t877a mutant in complex with s-1 (10.1074/JBC.M507464200 )
• 2AX8: crystal structure of the androgen receptor ligand binding domain w741l mutant in complex with s-1 (10.1074/JBC.M507464200 )
• 2AX9: crystal structure of the androgen receptor ligand binding domain in complex with r-3 (10.1074/JBC.M507464200 )
• 2AXA: crystal structure of the androgen receptor ligand binding domain in complex with s-1 (10.1074/JBC.M507464200 )
• 2HVC: the crystal structure of ligand-binding domain (lbd) of human androgen receptor in complex with a selective modulator lgd2226 (10.1107/S1744309106039340 )
• 2IHQ: crystal structure of the rat androgen receptor ligand binding domian complex with an n-aryl- hydroxybicyclohydantoin (10.1021/JM061101W )
• 2NW4: crystal structure of the rat androgen receptor ligand binding domain complex with bms-564929 (10.1210/EN.2006-0843 )
• 2OZ7: crystal structure of the human androgen receptor t877a mutant ligand- binding domain with cyproterone acetate (10.1074/JBC.M611711200 )
• 2PIO: androgen receptor lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PIP: androgen receptor lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PIQ: androgen receptor lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PIR: androgen receptor lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PIT: androgen receptor lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PIU: androgen receptor lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PIV: androgen receptor with small molecule (10.1073/PNAS.0708036104 )
• 2PIW: androgen receptor with small molecule (10.1073/PNAS.0708036104 )
• 2PIX: ar lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PKL: androgen receptor lbd with small molecule (10.1073/PNAS.0708036104 )
• 2PNU: crystal structure of human androgen receptor ligand-binding domain in complex with em-5744 (10.1074/JBC.M705524200 )
• 2Q7I: the wild type androgen receptor ligand binding domain bound with testosterone and an ar 20-30 peptide (10.1074/JBC.M703268200 )
• 2Q7J: the wild type androgen receptor ligand binding domain bound with testosterone and a tif2 box 3 coactivator peptide 740-753 (10.1074/JBC.M703268200 )
• 2Q7K: the androgen receptor prostate cancer mutant h874y ligand binding domain bound with testosterone and an ar 20-30 peptide (10.1074/JBC.M703268200 )
• 2Q7L: the androgen receptor prostate cancer mutant h874y ligand binding domain bound with testosterone and a tif2 box3 coactivator peptide 740-753 (10.1074/JBC.M703268200 )
• 2QPY: ar lbd with small molecule (10.1073/PNAS.0708036104 )
• 2YHD: human androgen receptor in complex with af2 small molecule inhibitor (10.1021/JM200532B )
• 2YLO: targeting the binding function 3 site of the androgen receptor through in silico molecular modeling (10.1021/JM201098N )
• 2YLP: targeting the binding function 3 site of the androgen receptor through in silico molecular modeling (10.1021/JM201098N )
• 2YLQ: targeting the binding function 3 site of the androgen receptor through in silico molecular modeling (10.1021/JM201098N )
• 2Z4J: crystal structure of ar lbd with shp peptide nr box 2 (10.1107/S0907444907045702 )
• 3B5R: crystal structure of the androgen receptor ligand binding domain in complex with sarm c-31 (10.1016/J.BMCL.2008.09.002 )
• 3B65: crystal structure of the androgen receptor ligand binding domain in complex with sarm s-24 (10.1016/J.BMCL.2008.09.002 )
• 3B66: crystal structure of the androgen receptor ligand binding domain in complex with sarm s-21 (10.1016/J.BMCL.2008.09.002 )
• 3B67: crystal structure of the androgen receptor ligand binding domain in complex with sarm c-23 (10.1016/J.BMCL.2008.09.002 )
• 3B68: crystal structure of the androgen receptor ligand binding domain in complex with sarm s-4 (10.1016/J.BMCL.2008.09.002 )
• 3G0W: crystal structure of the rat androgen receptor ligand binding domain complex with an n-aryl-oxazolidin 2-imine inhibitor (10.1021/JM801583J )
• 3L3X: crystal structure of dht-bound androgen receptor in complex with the first motif of steroid receptor coactivator 3 (10.1074/JBC.M109.085779 )
• 3L3Z: crystal structure of dht-bound androgen receptor in complex with the third motif of steroid receptor coactivator 3 (10.1074/JBC.M109.085779 )
• 3RLJ: crystal structure of the androgen receptor ligand binding domain in complex with sarm s-22 (10.1021/JM2000097 )
• 3RLL: crystal structure of the t877a androgen receptor ligand binding domain in complex with (s)-n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4- cyanonaphthalen-1-yloxy)-2-hydroxy-2-methylpropanamide (10.1021/JM2000097 )
• 3V49: structure of ar lbd with activator peptide and sarm inhibitor 1 (10.1021/JM300249M )
• 3V4A: structure of ar lbd with activator peptide and sarm inhibitor 2 (10.1021/JM300249M )
• 3ZQT: targeting the binding function 3 site of the androgen receptor through in silico molecular modeling (10.1021/JM201098N )
• 4HLW: targeting the binding function 3 (bf3) site of the human androgen receptor through virtual screening. 2. development of 2-((2- phenoxyethyl) thio)-1h-benzoimidazole derivatives. (10.1021/JM3015712 )
• 4K7A: crystal structure of the androgen receptor ligand binding domain in complex with minoxidil
• 4OEA: crystal structure of ar-lbd (10.1016/J.MOLONC.2014.06.009 )
• 4OED: crystal structure of ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OEY: crystal structure of ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OEZ: crystal structure of ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OFR: crystal structure of ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OFU: crystal structure of ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OGH: crystal structure of t877a-ar-lbd (10.1016/J.MOLONC.2014.06.009 )
• 4OH5: crystal structure of t877a-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OH6: crystal structure of t877a-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OHA: crystal structure of t877a-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OIL: crystal structure of t877a-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OIU: crystal structure of t877a-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OJ9: crystal structure of t877a-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OJB: crystal structure of w741l-ar-lbd (10.1016/J.MOLONC.2014.06.009 )
• 4OK1: crystal structure of w741l-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OKB: crystal structure of w741l-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OKT: crystal structure of w741l-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OKW: crystal structure of w741l-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OKX: crystal structure of w741l-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4OLM: crystal structure of w741l-ar-lbd bound with co-regulator peptide (10.1016/J.MOLONC.2014.06.009 )
• 4QL8: crystal structure of androgen receptor in complex with the ligand (10.1021/JM5009049 )
• 5CJ6: crystal structure of a selective androgen receptor modulator bound to the ligand binding domain of the human androgen receptor (10.1021/ACS.JMEDCHEM.5B01168 )
• 5JJM: crystal structure of homodimeric androgen receptor ligand-binding domain bound to dht and lxxll peptide (10.1038/NCOMMS14388 )
• 5T8E: synthesis and biological evaluation of novel selective androgen receptor modulators (sarms). part ii: optimization of 4-(pyrrolidin- 1-yl)benzonitrile derivatives (10.1016/J.BMCL.2017.03.038 )
• 5T8J: synthesis and biological evaluation of novel selective androgen receptor modulators (sarms). part ii: optimization of 4-(pyrrolidin- 1-yl)benzonitrile derivatives (10.1016/J.BMCL.2017.03.038 )
• 5V8Q: synthesis and biological evaluation of novel selective androgen receptor modulators (sarms): part iii (10.1016/J.BMC.2017.04.018 )
• 5VO4: crystal structure of the androgen receptor ligand binding domain in complex with 5-(2-fluoro-4-hydroxyphenyl)-1-methyl-1h-pyrrole-2- carbonitrile (10.1021/ACS.JMEDCHEM.7B00373 )